BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25898693)

  • 1. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
    Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
    J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
    Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
    Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
    Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
    Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
    Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
    Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
    Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
    Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
    Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
    J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
    Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
    Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
    Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
    Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma.
    Hernández Fernández de Rojas D; Antépara Ercoreca I; Ponte Tellechea A; Ibáñez Echevarría E; Jáuregui Presa I; Gamboa Setién P; Asturias JA; Landeta Manzano A; Madariaga Goirigolzarri B
    Immunotherapy; 2015; 7(2):89-99. PubMed ID: 25659029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-Dependent Immunological Responses after a 6-Month Course of Sublingual House Dust Mite Immunotherapy in Patients with Allergic Rhinitis.
    Didier A; Campo P; Moreno F; Durand-Perdriel F; Marin A; Chartier A
    Int Arch Allergy Immunol; 2015; 168(3):182-92. PubMed ID: 26789997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
    Jung K
    Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy.
    Moreno V; Alvariño M; Rodríguez F; Roger A; Peña-Arellano MI; Lleonart R; Pagán JA; Navarro JA; Navarro LA; Vidal C; Ponte-Tellechea A; Gómez-Fernández MC; Madariaga-Goirigolzarri B; Asturias JA; Hernández-Fernandez de Rojas D
    Immunotherapy; 2016; 8(3):265-77. PubMed ID: 26757045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Differences in Serum Quantitative Specific IgE Levels Induced by Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis Sensitization in Intermittent and Persistent Allergic Asthma.
    Susanto AJ; Rengganis I; Rumende CM; Harimurti K
    Acta Med Indones; 2017 Oct; 49(4):299-306. PubMed ID: 29348379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in IL-10 and specific antibodies associated to successful Dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment.
    Martín-Muñoz MF; Pineda F; Muiños T; Fontan M; Nevot S; Bosque M; Jurado Palomo J; Torredemer A; Valdesoiro L; Martinez Cañavate AM; Pedemonte Marco C;
    Allergol Immunopathol (Madr); 2013; 41(1):4-10. PubMed ID: 22321665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.